Encicarb Injection (Ferric Carboxymaltose)

Iron deficiency anemia (IDA) is one of the most prevalent health conditions that affects thousands of people, specifically pregnant women, mothers, as well as patients suffering from chronic conditions. If oral iron therapy proves unsatisfactory, difficult to tolerate, or slow enough to treat severe anemia, intravenous (IV) iron can be the fastest, most efficient alternative.

Encicarb Injection that contains Ferric Carboxymaltose is a new IV iron formula that is designed to provide the safe administration of high doses in one sitting. It is widely used in clinics and hospitals for quick replenishment of iron stores and to restore hemoglobin levels.

In this comprehensive guide, we’ll discuss the use of the mechanism, dosage, positives, negative effects, and warnings associated with Encicarb (Ferric Carboxymaltose), aiding health professionals and patients to understand the importance of it in managing iron deficiencies.

What is Encicarb Injection?

Encicarb can be described as an injectable, prescription-only iron preparation with ferric Carboxymaltose, which is a solid iron-carbohydrate compound. It’s indicated for the treatment of anemia due to iron deficiency, especially in the following situations:

• Iron supplements for oral use are not effective or do not have the desired effect
• A rapid repletion of iron is necessary (e.g., extreme anemia)
• The loss of blood continues (e.g. or in the menstrual or digestive bleeding)
• The patient has chronic kidney disease (CKD), heart failure, or inflammatory bowel disease (IBD)

Ferric carboxymaltose permits higher doses of single-dose infusions (up to 1000 mg) compared to older IV iron formulations, thus reducing the necessity for several hospitalizations.

How Does Ferric Carboxymaltose Work?

Iron is vital to the creation of hemoglobin, which is the oxygen-carrying protein within the red blood cells. If there isn’t enough iron in the body, the body won’t be able to make enough hemoglobin. This causes anemia, fatigue, and shortness of breath, and other indications of anemia.

Encicarb (Ferric Carboxymaltose) is a potent iron-containing ingredient that enters the bloodstream. After administration:

1. The iron-carboxymaltose compound is digested by macrophages before being slowly disintegrated.
2. Iron is released through the plasma. It is bound to transferrin, which is the protein which is responsible for the delivery of iron into the bone marrow.
3. Iron then gets incorporated into hemoglobin when red blood cell production.

This route is a bypass of the digestive tract, which makes it suitable for patients suffering from difficulties with absorption or an intolerance to iron taken orally.

Indications: Who Should Receive Encicarb?

Encicarb is most commonly used by the adult population and in select pediatric patients using:

• Anemia due to iron deficiency, where oral iron is ineffective or impractical
• Chronic kidney disease (especially those on dialysis or erythropoietin therapy)
• Inflammatory bowel disease (Crohn’s disease, ulcerative colitis)
• Heavy menstrual bleeding
• Peripartum or postpartum anemia
• Heart failure with concurrent iron deficiency
• Preoperative anemia (to reduce need for blood transfusion)

The practice is increasingly being used for oncology and surgical procedures as well as in intensive care.

Dosage and Administration

The dose of Encicarb can be adjusted based on your patient’s hemoglobin concentration, body weight, and iron deficiency.

General Dosing Guidelines:

• Maximum single dose: 1000 mg of elemental iron
• Administration route: Intravenous (IV) is available in a slow injection or as a diluted solution in saline for an infusion
• Frequency: Doses in one dose or repeated doses for at least 7 days between each in accordance with your iron requirements.

Example Dosing:

In the case of a healthy adult who weighs 60 kg who suffers from moderate anemia, a single infusion of 1000 mg might be sufficient. For severe situations, two doses separated by a week could be required.

Encicarb is advised not to be used with other drugs or administered through the same vein.

Benefits of Encicarb Injection

• Fast refill of stores in iron as well as hemoglobin
• Higher single-dose capacity (up to 1000 mg per session)
• No test dose required (unlike older IV irons)
• Fewer GI side effects than oral iron
• Improved quality of life in chronic disease-related anemia
• Safe for use in CKD, heart failure, and postpartum anemia
• Ideal for situations where oral absorption may be diminished

Due to these advantages, Encicarb has largely replaced traditional formulations, such as ferrous sucrose as well as the iron dextran, in numerous situations in clinical practice.

Onset of Action and Effectiveness

• Hemoglobin amounts usually begin to increase in the span of 7-10 working days
• The iron stores (ferritin, the transferrin molecule, saturation of transferrin) improve within 2-3 weeks
• Clinical symptoms such as fatigue, palpitations, and dizziness improve progressively as anemia corrects

A majority of patients report improved levels of energy and increased functioning capacity in the first 1 to 2 weeks after the treatment.

Side Effects of Encicarb (Ferric Carboxymaltose)

Encicarb is typically well-tolerated; however, like all medications, there are risks of side effects.

Common Side Effects:

• Headache
• Dizziness
• Nausea
• Injection site pain or discoloration
• Metallic taste
• Flushing or low-grade fever

Less Common but Serious Reactions:

• Hypersensitivity or anaphylaxis (rare)
• Low phosphate levels (hypophosphatemia)
• Hypertension during or after infusion
• Rash or pruritus
• Abdominal cramps

Patients must be closely monitored throughout and following infusion to look for indications of reactions to the medication, particularly when the infusion is administered for the first time.

Hypophosphatemia: A Noteworthy Concern

Ferric carboxymaltose was linked to transient hyperphosphatemia (low blood levels of phosphate), particularly in frequent dosages.

Symptoms:

• Muscle weakness
• Bone pain
• Fatigue
• In severe cases, risk of osteomalacia (bone softening)

Patients who are receiving several sessions or who have an already existing malnutrition or vitamin D deficiency should be observed.

Contraindications

Encicarb is contraindicated in:

• Known hypersensitivity to ferric carboxymaltose
• Anemia not caused by iron deficiency (e.g., hemolytic anemia, B12 deficiency)
• Iron overload (e.g., hemochromatosis)
• Active infections (IV iron can promote bacterial growth)

The use of this method is for pregnant women only in cases of clear indication, usually in the third or second trimester.

Monitoring During and After Treatment

To ensure safety and efficient utilization, medical professionals are usually on the lookout for:

• Hemoglobin (Hb) and hematocrit
• Serum ferritin and transferrin saturation (TSAT)
• Phosphate levels (especially in high-dose or repeated use)
• Liver function and vital signs during infusion
• Response to therapy (resolution of anemia symptoms)

How Encicarb Compares to Other IV Iron Formulations

Encicarb is a practical, quick, efficient, and fast alternative for large-dose iron supply with very few infusion-related issues.

Conclusion

Encicarb Injection (Ferric Carboxymaltose) is an innovative solution for the most enduring problem, iron shortage. Because of its capability to deliver huge doses of iron without risk quickly and efficiently, Encicarb helps patients recover from anemia faster than traditional oral iron and IV treatments. Encicarb has been a top option in a variety of clinical situations, particularly when rapid correction is required or when treatment with oral medication does not work.

Like any other medical procedure, proper diagnosis, careful doses, and constant surveillance are vital in order to guarantee safety and maximise advantages. Patients who are receiving Encicarb must remain in constant communication with their doctor, be sure to report any adverse reactions promptly, and keep addressing the root causes behind their anemia.